Genomic Health Stock Price, News & Analysis (NASDAQ:GHDX)

$28.70 -0.34 (-1.17 %)
(As of 11/17/2017 04:00 PM ET)
Previous Close$29.04
Today's Range$28.49 - $29.00
52-Week Range$26.37 - $34.02
Volume77,560 shs
Average Volume118,810 shs
Market Capitalization$987.21 million
P/E RatioN/A
Dividend YieldN/A
Beta0.72

About Genomic Health (NASDAQ:GHDX)

Genomic Health logoGenomic Health, Inc. is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company's Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test. Its research and development activities are focused on developing a pipeline of tests to optimize the treatment of various cancers including breast, colon, prostate and other cancers. It offers its Oncotype DX tests as a clinical laboratory service, where it analyzes the expression levels of genes in tumor tissue samples and provides physicians with a quantitative gene expression profile expressed as a single quantitative score, which it calls a Recurrence Score for invasive breast cancer and colon cancer, a DCIS Score for ductal carcinoma in situ (DCIS), and a Genomic Prostate Score, for prostate cancer.


Industry, Sector and Symbol:
  • Industry: Biotechnology & Medical Research
  • Sub-Industry: Biotechnology
  • Sector: Medical
  • Symbol: NASDAQ:GHDX
  • CUSIP: 37244C10
  • Web: www.genomichealth.com
Debt:
  • Current Ratio: 3.74%
  • Quick Ratio: 3.74%
Sales & Book Value:
  • Annual Sales: $327.87 million
  • Price / Sales: 3.04
  • Book Value: $5.02 per share
  • Price / Book: 5.72
Profitability:
  • Trailing EPS: ($0.12)
  • Net Income: ($13,910,000.00)
  • Net Margins: -1.30%
  • Return on Equity: -1.79%
  • Return on Assets: -1.41%
Misc:
  • Employees: 846
  • Outstanding Shares: 34,780,000
 
Frequently Asked Questions for Genomic Health (NASDAQ:GHDX)

What is Genomic Health's stock symbol?

Genomic Health trades on the NASDAQ under the ticker symbol "GHDX."

How were Genomic Health's earnings last quarter?

Genomic Health, Inc. (NASDAQ:GHDX) released its quarterly earnings results on Tuesday, November, 1st. The medical research company reported ($0.08) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.09) by $0.01. The medical research company had revenue of $82.30 million for the quarter, compared to analysts' expectations of $83.24 million. Genomic Health had a negative net margin of 1.30% and a negative return on equity of 1.79%. The business's revenue was up 11.8% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.36) EPS. View Genomic Health's Earnings History.

When will Genomic Health make its next earnings announcement?

Genomic Health is scheduled to release their next quarterly earnings announcement on Monday, February, 12th 2018. View Earnings Estimates for Genomic Health.

Where is Genomic Health's stock going? Where will Genomic Health's stock price be in 2017?

7 equities research analysts have issued 1 year price targets for Genomic Health's stock. Their forecasts range from $27.00 to $39.00. On average, they expect Genomic Health's stock price to reach $32.67 in the next twelve months. View Analyst Ratings for Genomic Health.

Who are some of Genomic Health's key competitors?

Who are Genomic Health's key executives?

Genomic Health's management team includes the folowing people:

  • Kimberly J. Popovits, Chairman of the Board, President, Chief Executive Officer (Age 58)
  • Gordon Bradley Cole, Chief Financial Officer, Chief Operating Officer (Age 61)
  • Steven Shak M.D., Chief Scientific Officer (Age 66)
  • Phillip Febbo M.D., Chief Medical Officer (Age 50)
  • Laura Leber Kammeyer, Chief Communications Officer (Age 54)
  • Frederic Pla Ph.D., Chief Business and Product Development Officer
  • James Vaughn, Chief Commercial Officer
  • Julian C. Baker, Lead Independent Director (Age 50)
  • Felix J. Baker Ph.D., Independent Director (Age 47)
  • Fred E. Cohen Ph.D. M.D., Independent Director (Age 60)

Who owns Genomic Health stock?

Genomic Health's stock is owned by many different of retail and institutional investors. Top institutional investors include Schwab Charles Investment Management Inc. (1.45%), Eagle Asset Management Inc. (1.01%), American Century Companies Inc. (0.51%), Prudential Financial Inc. (0.51%), Cowen Prime Services LLC (0.36%) and Citadel Advisors LLC (0.27%). Company insiders that own Genomic Health stock include Felix Baker, Fred E Cohen, G Bradley Cole, James J Vaughn, Kimberly J Popovits, Laura Leber, Phillip G Febbo, Randall S Livingston and Steven Shak. View Institutional Ownership Trends for Genomic Health.

Who sold Genomic Health stock? Who is selling Genomic Health stock?

Genomic Health's stock was sold by a variety of institutional investors in the last quarter, including Eagle Asset Management Inc., Oppenheimer & Co. Inc., Prudential Financial Inc. and California State Teachers Retirement System. Company insiders that have sold Genomic Health company stock in the last year include Fred E Cohen, G Bradley Cole, James J Vaughn, Kimberly J Popovits, Laura Leber, Phillip G Febbo and Steven Shak. View Insider Buying and Selling for Genomic Health.

Who bought Genomic Health stock? Who is buying Genomic Health stock?

Genomic Health's stock was purchased by a variety of institutional investors in the last quarter, including Citadel Advisors LLC, American Century Companies Inc., Cowen Prime Services LLC, Los Angeles Capital Management & Equity Research Inc., Point72 Asset Management L.P., Nordea Investment Management AB, OxFORD Asset Management LLP and Wells Fargo & Company MN. View Insider Buying and Selling for Genomic Health.

How do I buy Genomic Health stock?

Shares of Genomic Health can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Genomic Health's stock price today?

One share of Genomic Health stock can currently be purchased for approximately $28.70.

How big of a company is Genomic Health?

Genomic Health has a market capitalization of $987.21 million and generates $327.87 million in revenue each year. The medical research company earns ($13,910,000.00) in net income (profit) each year or ($0.12) on an earnings per share basis. Genomic Health employs 846 workers across the globe.

How can I contact Genomic Health?

Genomic Health's mailing address is 301 PENOBSCOT DRIVE, REDWOOD CITY CA, 94063. The medical research company can be reached via phone at 650-556-9300 or via email at investors@genomichealth.com.


MarketBeat Community Rating for Genomic Health (NASDAQ GHDX)
Community Ranking:  1.8 out of 5 (star)
Outperform Votes:  156 (Vote Outperform)
Underperform Votes:  267 (Vote Underperform)
Total Votes:  423
MarketBeat's community ratings are surveys of what our community members think about Genomic Health and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Ratings for Genomic Health (NASDAQ:GHDX) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 5 Hold Ratings, 1 Buy Rating, 0 Strong Buy Ratings
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: $32.67 (13.82% upside)
Consensus Price Target History for Genomic Health (NASDAQ:GHDX)
Price Target History for Genomic Health (NASDAQ:GHDX)
Analysts' Ratings History for Genomic Health (NASDAQ:GHDX)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/15/2017Canaccord GenuityReiterated RatingBuy$39.00N/AView Rating Details
10/20/2017Jefferies Group LLCReiterated RatingHold$34.00N/AView Rating Details
9/1/2017Cowen and CompanyReiterated RatingHold$34.00LowView Rating Details
8/3/2017Piper Jaffray CompaniesReiterated RatingHold$31.00LowView Rating Details
5/3/2017Raymond James Financial, Inc.Reiterated RatingOutperform -> Market PerformHighView Rating Details
1/18/2017Deutsche Bank AGReiterated RatingHold$31.00N/AView Rating Details
1/9/2017Barclays PLCReiterated RatingSell$27.00N/AView Rating Details
8/3/2016Bank of America CorporationSet Price TargetSell$28.00N/AView Rating Details
6/21/2016Leerink SwannReiterated RatingBuyN/AView Rating Details
(Data available from 11/17/2015 forward)

Earnings

Earnings History for Genomic Health (NASDAQ:GHDX)
Earnings by Quarter for Genomic Health (NASDAQ:GHDX)
Earnings History by Quarter for Genomic Health (NASDAQ GHDX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/12/2018$0.08N/AView Earnings Details
8/1/2017Q2 2017($0.06)($0.08)$86.08 million$85.50 millionViewListenView Earnings Details
5/9/2017Q1 2017($0.06)($0.07)$86.21 million$84.00 millionViewListenView Earnings Details
2/14/2017Q416($0.01)$0.04$84.08 million$82.70 millionViewListenView Earnings Details
11/1/2016Q316($0.09)($0.08)$83.24 million$82.30 millionViewN/AView Earnings Details
8/2/2016Q216($0.18)($0.18)$81.27 million$81.97 millionViewN/AView Earnings Details
5/4/2016Q1($0.24)($0.19)$78.12 million$80.89 millionViewN/AView Earnings Details
2/10/2016Q415($0.09)($0.10)$74.03 million$74.50 millionViewListenView Earnings Details
11/3/2015Q315($0.18)($0.36)$73.35 million$73.60 millionViewN/AView Earnings Details
8/4/2015Q215($0.27)($0.29)$71.65 million$70.60 millionViewListenView Earnings Details
5/5/2015Q115($0.28)($0.30)$69.30 million$68.15 millionViewN/AView Earnings Details
2/10/2015Q414($0.21)($0.20)$72.20 million$69.10 millionViewN/AView Earnings Details
11/4/2014Q314($0.22)($0.20)$71.00 million$69.10 millionViewN/AView Earnings Details
8/7/2014Q214($0.28)($0.15)$69.04 million$70.50 millionViewN/AView Earnings Details
5/6/2014Q114($0.18)($0.24)$68.47 million$67.00 millionViewN/AView Earnings Details
2/4/2014Q413($0.03)($0.30)$69.20 million$68.80 millionViewN/AView Earnings Details
11/5/2013Q313($0.04)$0.02$64.98 million$65.99 millionViewN/AView Earnings Details
7/31/2013Q2 2013($0.08)($0.10)$63.91 million$63.70 millionViewN/AView Earnings Details
5/2/2013Q1 2013($0.02)($0.03)$62.90 million$63.10 millionViewN/AView Earnings Details
2/6/2013Q4 2012$0.03$0.06$58.90 million$60.40 millionViewN/AView Earnings Details
11/7/2012Q312$0.05$0.11$59.87 million$58.60 millionViewN/AView Earnings Details
8/8/2012($0.02)$0.06ViewN/AView Earnings Details
5/2/2012($0.02)$0.02ViewN/AView Earnings Details
2/6/2012$0.09$0.08ViewN/AView Earnings Details
11/1/2011$0.03$0.10ViewN/AView Earnings Details
8/3/2011$0.02$0.08ViewN/AView Earnings Details
5/3/2011$0.02($0.01)ViewN/AView Earnings Details
2/8/2011$0.06$0.06ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Genomic Health (NASDAQ:GHDX)
2017 EPS Consensus Estimate: ($0.02)
2018 EPS Consensus Estimate: $0.29
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.08)$0.02($0.03)
Q2 20172($0.07)($0.07)($0.07)
Q3 20172($0.01)$0.02$0.01
Q4 20172$0.07$0.08$0.08
Q1 20182$0.07$0.07$0.07
Q2 20182$0.02$0.07$0.05
Q3 20182$0.07$0.07$0.07
Q4 20182$0.08$0.13$0.11
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Genomic Health (NASDAQ:GHDX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Genomic Health (NASDAQ GHDX)
Insider Ownership Percentage: 46.20%
Institutional Ownership Percentage: 89.13%
Insider Trades by Quarter for Genomic Health (NASDAQ:GHDX)
Institutional Ownership by Quarter for Genomic Health (NASDAQ:GHDX)
Insider Trades by Quarter for Genomic Health (NASDAQ GHDX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/7/2017G Bradley ColeCOOSell5,000$31.47$157,350.00View SEC Filing  
11/2/2017James J. VaughnInsiderSell1,379$32.51$44,831.29View SEC Filing  
10/10/2017G Bradley ColeCOOSell5,000$31.93$159,650.00View SEC Filing  
9/14/2017Kimberly J. PopovitsInsiderSell5,000$31.00$155,000.00View SEC Filing  
9/12/2017G Bradley ColeCOOSell5,000$31.86$159,300.00View SEC Filing  
8/14/2017Kimberly J. PopovitsInsiderSell5,000$30.22$151,100.00View SEC Filing  
8/8/2017G Bradley ColeCOOSell5,000$30.57$152,850.00View SEC Filing  
8/8/2017James J. VaughnInsiderSell8,000$30.59$244,720.00View SEC Filing  
7/19/2017Phillip G. FebboInsiderSell3,174$33.57$106,551.18View SEC Filing  
7/11/2017G Bradley ColeCOOSell5,000$32.53$162,650.00View SEC Filing  
7/5/2017Kimberly J. PopovitsInsiderSell5,000$32.59$162,950.00View SEC Filing  
7/5/2017Kimberly J. PopovitsCEOSell1,468$32.67$47,959.56View SEC Filing  
6/23/2017Steven ShakInsiderSell5,000$33.27$166,350.00View SEC Filing  
6/5/2017Kimberly J. PopovitsInsiderSell5,000$32.32$161,600.00View SEC Filing  
5/23/2017Steven ShakInsiderSell5,000$29.40$147,000.00View SEC Filing  
5/19/2017Fred E CohenDirectorSell8,250$29.54$243,705.00View SEC Filing  
5/18/2017Fred E CohenDirectorSell16,500$29.88$493,020.00View SEC Filing  
5/16/2017Fred E CohenDirectorSell8,250$30.68$253,110.00View SEC Filing  
5/3/2017Kimberly J. PopovitsInsiderSell5,000$31.77$158,850.00View SEC Filing  
4/24/2017Steven ShakInsiderSell5,000$31.46$157,300.00View SEC Filing  
4/3/2017Kimberly J. PopovitsInsiderSell5,000$31.30$156,500.00View SEC Filing  
3/23/2017Steven ShakInsiderSell5,000$31.26$156,300.00View SEC Filing  
3/20/2017Laura LeberInsiderSell3,072$31.88$97,935.36View SEC Filing  
3/6/2017Kimberly J. PopovitsInsiderSell5,000$31.09$155,450.00View SEC Filing  
2/16/2017Phillip G. FebboInsiderSell2,495$30.09$75,074.55View SEC Filing  
1/23/2017Steven ShakInsiderSell5,000$27.28$136,400.00View SEC Filing  
1/10/2017G Bradley ColeCOOSell5,000$29.22$146,100.00View SEC Filing  
12/5/2016Kimberly J PopovitsInsiderSell5,000$30.02$150,100.00View SEC Filing  
11/3/2016Kimberly J PopovitsInsiderSell5,313$28.88$153,439.44View SEC Filing  
10/11/2016Steven ShakInsiderSell5,000$30.39$151,950.00View SEC Filing  
10/10/2016G Bradley ColeCOOSell8,290$30.59$253,591.10View SEC Filing  
10/6/2016James J. VaughnInsiderSell3,000$29.68$89,040.00View SEC Filing  
9/13/2016Steven ShakInsiderSell5,000$26.83$134,150.00View SEC Filing  
8/23/2016Steven ShakInsiderSell5,000$27.24$136,200.00View SEC Filing  
8/15/2016Felix BakerDirectorBuy100,000$27.02$2,702,000.00View SEC Filing  
8/11/2016G Bradley ColeCOOSell5,000$28.87$144,350.00View SEC Filing  
8/8/2016James J. VaughnInsiderSell3,000$28.74$86,220.00View SEC Filing  
7/19/2016Steven ShakInsiderSell5,000$27.42$137,100.00View SEC Filing  
7/6/2016G Bradley ColeCOOSell5,000$26.64$133,200.00View SEC Filing  
6/21/2016Steven ShakInsiderSell5,000$25.77$128,850.00View SEC Filing  
6/9/2016G Bradley ColeCOOSell5,000$26.62$133,100.00View SEC Filing  
6/6/2016James J VaughnInsiderSell1,997$28.00$55,916.00View SEC Filing  
5/16/2016G Bradley ColeCOOSell5,000$27.60$138,000.00View SEC Filing  
5/10/2016Phillip G FebboInsiderSell6,324$27.20$172,012.80View SEC Filing  
5/4/2016Steven ShakInsiderSell10,000$25.43$254,300.00View SEC Filing  
1/13/2016Randall S. LivingstonDirectorSell1,250$32.14$40,175.00View SEC Filing  
1/12/2016G Bradley ColeCOOSell4,000$31.69$126,760.00View SEC Filing  
1/7/2016James J. VaughninsiderSell2,000$33.63$67,260.00View SEC Filing  
12/8/2015G Bradley ColeCOOSell4,000$29.26$117,040.00View SEC Filing  
12/7/2015James J. VaughninsiderSell2,000$29.33$58,660.00View SEC Filing  
11/10/2015G Bradley ColeCOOSell4,000$26.03$104,120.00View SEC Filing  
9/9/2015G Bradley ColeCOOSell9,664$25.35$244,982.40View SEC Filing  
7/7/2015G Bradley ColeCOOSell4,000$27.53$110,120.00View SEC Filing  
6/9/2015G Bradley ColeCOOSell4,000$26.24$104,960.00View SEC Filing  
4/13/2015Kimberly J PopovitsCEOSell3,000$31.28$93,840.00View SEC Filing  
4/7/2015G Bradley ColeCOOSell4,000$30.44$121,760.00View SEC Filing  
2/2/2015Randall S LivingstonDirectorSell1,000$31.93$31,930.00View SEC Filing  
1/12/2015Kimberly J PopovitsCEOSell3,000$33.46$100,380.00View SEC Filing  
12/8/2014G Bradley ColeCOOSell4,336$32.52$141,006.72View SEC Filing  
11/12/2014Kimberly J PopovitsCEOSell4,300$34.82$149,726.00View SEC Filing  
10/13/2014Kimberly J PopovitsCEOSell3,000$30.78$92,340.00View SEC Filing  
10/8/2014G Bradley ColeCOOSell4,000$28.77$115,080.00View SEC Filing  
9/11/2014Kimberly J PopovitsCEOSell3,000$29.82$89,460.00View SEC Filing  
9/8/2014G Bradley ColeCOOSell4,700$30.09$141,423.00View SEC Filing  
8/14/2014Steven ShakEVPSell13,348$27.36$365,201.28View SEC Filing  
8/13/2014Steven ShakEVPSell7,000$27.25$190,750.00View SEC Filing  
7/14/2014Kimberly J PopovitsCEOSell3,000$26.59$79,770.00View SEC Filing  
7/8/2014G Bradley ColeCOOSell2,300$27.05$62,215.00View SEC Filing  
7/1/2014Steven ShakEVPSell7,000$27.00$189,000.00View SEC Filing  
4/14/2014Steven ShakEVPSell7,000$26.25$183,750.00View SEC Filing  
4/8/2014G Bradley ColeCOOSell3,000$27.00$81,000.00View SEC Filing  
3/14/2014Steven ShakEVPSell7,000$28.36$198,520.00View SEC Filing  
2/18/2014Kathy HibbsSVPSell1,312$27.88$36,578.56View SEC Filing  
1/15/2014Steven ShakEVPSell7,000$31.51$220,570.00View SEC Filing  
1/13/2014Kimberly PopovitsCEOSell2,500$30.00$75,000.00View SEC Filing  
12/17/2013Steven ShakCMOSell14,000$29.57$413,980.00View SEC Filing  
12/12/2013Kimberly PopovitsCEOSell2,500$30.68$76,700.00View SEC Filing  
12/9/2013Dean SchornoCFOSell3,000$33.25$99,750.00View SEC Filing  
10/15/2013Steven ShakCMOSell5,000$29.67$148,350.00View SEC Filing  
10/10/2013Kimberly PopovitsCEOSell2,500$30.00$75,000.00View SEC Filing  
10/9/2013G Bradley ColeCOOSell2,500$29.95$74,875.00View SEC Filing  
9/18/2013Steven ShakCMOSell5,000$33.73$168,650.00View SEC Filing  
9/12/2013Kimberly PopovitsCEOSell2,500$34.31$85,775.00View SEC Filing  
9/9/2013G Bradley ColeCOOSell2,500$32.53$81,325.00View SEC Filing  
9/6/2013Dean L SchornoCFOSell4,000$32.90$131,600.00View SEC Filing  
9/3/2013Randall LivingstonDirectorSell1,000$31.49$31,490.00View SEC Filing  
8/14/2013Steven ShakCMOSell5,000$32.98$164,900.00View SEC Filing  
8/12/2013Kimberly PopovitsCEOSell2,500$33.03$82,575.00View SEC Filing  
8/9/2013Dean SchornoCFOSell4,000$33.15$132,600.00View SEC Filing  
8/7/2013G Bradley ColeCOOSell2,500$33.66$84,150.00View SEC Filing  
7/23/2013Steven ShakCMOSell5,000$35.33$176,650.00View SEC Filing  
7/12/2013Kimberly J PopovitsCEOSell5,000$34.61$173,050.00View SEC Filing  
7/9/2013Dean L SchornoCFOSell4,000$33.81$135,240.00View SEC Filing  
7/8/2013G Bradley ColeCOOSell2,500$33.33$83,325.00View SEC Filing  
6/18/2013Steven ShakCMOSell5,000$33.52$167,600.00View SEC Filing  
6/12/2013Kimberly J PopovitsCEOSell5,000$35.68$178,400.00View SEC Filing  
6/10/2013Dean L SchornoCFOSell4,000$35.88$143,520.00View SEC Filing  
6/5/2013Felix BakerDirectorBuy381,432$36.16$13,792,581.12View SEC Filing  
6/5/2013G Bradley ColeCOOSell2,500$36.47$91,175.00View SEC Filing  
6/3/2013Felix BakerDirectorBuy179,583$36.71$6,592,491.93View SEC Filing  
5/29/2013Felix BakerDirectorBuy121,266$36.89$4,473,502.74View SEC Filing  
5/24/2013Felix BakerDirectorBuy79,417$36.93$2,932,869.81View SEC Filing  
5/22/2013Kathy L HibbsSVPSell1,000$37.48$37,480.00View SEC Filing  
5/21/2013Steven ShakCMOSell5,000$37.19$185,950.00View SEC Filing  
5/16/2013Felix BakerDirectorBuy71,439$36.45$2,603,951.55View SEC Filing  
5/15/2013Randall S LivingstonDirectorSell1,337$35.83$47,904.71View SEC Filing  
5/14/2013Felix BakerDirectorBuy240,426$34.34$8,256,228.84View SEC Filing  
5/13/2013Kathy L HibbsSVPSell1,250$34.42$43,025.00View SEC Filing  
5/13/2013Kimberly J PopovitsCEOSell5,000$34.70$173,500.00View SEC Filing  
5/9/2013Dean L SchornoCFOSell4,000$36.02$144,080.00View SEC Filing  
5/8/2013G Bradley ColeCOOSell2,500$35.99$89,975.00View SEC Filing  
2/21/2013Felix BakerDirectorBuy49,085$27.78$1,363,581.30View SEC Filing  
2/14/2013Woodrow A Myers JrDirectorSell41,250$28.40$1,171,500.00View SEC Filing  
2/11/2013Felix BakerDirectorBuy116,360$28.15$3,275,534.00View SEC Filing  
11/26/2012Randall S LivingstonDirectorSell2,000$27.84$55,680.00View SEC Filing  
11/21/2012Felix BakerDirectorBuy229,300$26.83$6,152,119.00View SEC Filing  
11/14/2012Felix BakerDirectorBuy103,167$27.32$2,818,522.44View SEC Filing  
11/13/2012Felix BakerDirectorBuy823,772$27.81$22,909,099.32View SEC Filing  
11/12/2012Dean L SchornoCFOSell3,000$28.00$84,000.00View SEC Filing  
11/8/2012G Bradley ColeCOOSell2,500$28.62$71,550.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Genomic Health (NASDAQ:GHDX)
Latest Headlines for Genomic Health (NASDAQ GHDX)
Source:
DateHeadline
Genomic Health Cancer Diagnostic Tests Grow Amid Cost WoesGenomic Health Cancer Diagnostic Tests Grow Amid Cost Woes
finance.yahoo.com - November 17 at 5:38 PM
Biocartis Group NV: BIOCARTIS Q3 2017 BUSINESS UPDATEBiocartis Group NV: BIOCARTIS Q3 2017 BUSINESS UPDATE
finance.yahoo.com - November 16 at 2:43 PM
Canaccord Genuity Reaffirms "Buy" Rating for Genomic Health, Inc. (GHDX)Canaccord Genuity Reaffirms "Buy" Rating for Genomic Health, Inc. (GHDX)
www.americanbankingnews.com - November 15 at 11:43 AM
Genomic Health, Inc. (GHDX) Expected to Earn FY2017 Earnings of ($0.09) Per ShareGenomic Health, Inc. (GHDX) Expected to Earn FY2017 Earnings of ($0.09) Per Share
www.americanbankingnews.com - November 15 at 6:56 AM
Brokers Set Expectations for Genomic Health, Inc.s Q1 2018 Earnings (GHDX)Brokers Set Expectations for Genomic Health, Inc.'s Q1 2018 Earnings (GHDX)
www.americanbankingnews.com - November 14 at 9:26 AM
FY2017 EPS Estimates for Genomic Health, Inc. Cut by Jefferies Group (GHDX)FY2017 EPS Estimates for Genomic Health, Inc. Cut by Jefferies Group (GHDX)
www.americanbankingnews.com - November 13 at 3:36 AM
Q4 2017 EPS Estimates for Genomic Health, Inc. (GHDX) Reduced by AnalystQ4 2017 EPS Estimates for Genomic Health, Inc. (GHDX) Reduced by Analyst
www.americanbankingnews.com - November 10 at 8:48 AM
Genomic Health, Inc. (GHDX) Cut to Sell at ValuEngineGenomic Health, Inc. (GHDX) Cut to Sell at ValuEngine
www.americanbankingnews.com - November 10 at 12:58 AM
Genomic Health, Inc. (GHDX) COO G Bradley Cole Sells 5,000 SharesGenomic Health, Inc. (GHDX) COO G Bradley Cole Sells 5,000 Shares
www.americanbankingnews.com - November 9 at 7:29 PM
Genomic Health Announces Third Quarter 2017 Financial Results and Reports Recent Business ProgressGenomic Health Announces Third Quarter 2017 Financial Results and Reports Recent Business Progress
finance.yahoo.com - November 9 at 6:04 AM
Genomic Health reports 3Q lossGenomic Health reports 3Q loss
finance.yahoo.com - November 9 at 6:04 AM
Edited Transcript of GHDX earnings conference call or presentation 8-Nov-17 9:30pm GMTEdited Transcript of GHDX earnings conference call or presentation 8-Nov-17 9:30pm GMT
finance.yahoo.com - November 9 at 6:04 AM
Genomic Health, Inc. (GHDX) Given Average Rating of "Hold" by BrokeragesGenomic Health, Inc. (GHDX) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - November 9 at 3:38 AM
$87.06 Million in Sales Expected for Genomic Health, Inc. (GHDX) This Quarter$87.06 Million in Sales Expected for Genomic Health, Inc. (GHDX) This Quarter
www.americanbankingnews.com - November 9 at 2:46 AM
Genomic Health, Inc. (GHDX) Insider Sells $44,831.29 in StockGenomic Health, Inc. (GHDX) Insider Sells $44,831.29 in Stock
www.americanbankingnews.com - November 8 at 7:58 PM
GHDX Crosses Below Key Moving Average LevelGHDX Crosses Below Key Moving Average Level
www.nasdaq.com - November 8 at 7:59 AM
Genomic Health to Announce Third Quarter 2017 Financial Results and Host Conference Call on Wednesday, November 8, 2017Genomic Health to Announce Third Quarter 2017 Financial Results and Host Conference Call on Wednesday, November 8, 2017
finance.yahoo.com - November 1 at 8:36 PM
Genomic Health, Inc. (GHDX) Scheduled to Post Earnings on WednesdayGenomic Health, Inc. (GHDX) Scheduled to Post Earnings on Wednesday
www.americanbankingnews.com - November 1 at 8:08 PM
Genomic Health, Inc. (GHDX) Set to Announce Quarterly Earnings on MondayGenomic Health, Inc. (GHDX) Set to Announce Quarterly Earnings on Monday
www.americanbankingnews.com - October 23 at 9:20 AM
Equities Analysts Set Expectations for Genomic Health, Inc.s Q3 2017 Earnings (GHDX)Equities Analysts Set Expectations for Genomic Health, Inc.'s Q3 2017 Earnings (GHDX)
www.americanbankingnews.com - October 23 at 1:50 AM
Genomic Health, Inc. (GHDX) Rating Reiterated by Jefferies Group LLCGenomic Health, Inc. (GHDX) Rating Reiterated by Jefferies Group LLC
www.americanbankingnews.com - October 21 at 5:26 PM
Genomic Health, Inc. (GHDX) Expected to Announce Quarterly Sales of $87.06 MillionGenomic Health, Inc. (GHDX) Expected to Announce Quarterly Sales of $87.06 Million
www.americanbankingnews.com - October 21 at 2:54 PM
Financial Analysis: Genomic Health (GHDX) & Its PeersFinancial Analysis: Genomic Health (GHDX) & Its Peers
www.americanbankingnews.com - October 17 at 2:08 PM
Genomic Health, Inc. (GHDX) Receives Consensus Recommendation of "Hold" from BrokeragesGenomic Health, Inc. (GHDX) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - October 15 at 4:46 AM
Genomic Health, Inc. (GHDX) Raised to Hold at Zacks Investment ResearchGenomic Health, Inc. (GHDX) Raised to Hold at Zacks Investment Research
www.americanbankingnews.com - October 13 at 1:54 PM
Genomic Health, Inc. (GHDX) COO Sells $159,650.00 in StockGenomic Health, Inc. (GHDX) COO Sells $159,650.00 in Stock
www.americanbankingnews.com - October 11 at 7:50 PM
Zacks Investment Research Lowers Genomic Health, Inc. (GHDX) to SellZacks Investment Research Lowers Genomic Health, Inc. (GHDX) to Sell
www.americanbankingnews.com - October 8 at 7:20 PM
Genomic Healths Cost Pressure Mounts, Cancer Tests StrongGenomic Health's Cost Pressure Mounts, Cancer Tests Strong
finance.yahoo.com - October 5 at 11:45 PM
Genomic Health, Inc. (GHDX) Earns "Buy" Rating from Canaccord GenuityGenomic Health, Inc. (GHDX) Earns "Buy" Rating from Canaccord Genuity
www.americanbankingnews.com - October 1 at 5:14 PM
Contrasting Genomic Health (GHDX) & Inovio Pharmaceuticals (INO)Contrasting Genomic Health (GHDX) & Inovio Pharmaceuticals (INO)
www.americanbankingnews.com - September 28 at 10:50 PM
Genomic Health, Inc. breached its 50 day moving average in a Bullish Manner : GHDX-US : September 27, 2017Genomic Health, Inc. breached its 50 day moving average in a Bullish Manner : GHDX-US : September 27, 2017
finance.yahoo.com - September 27 at 8:34 AM
ETFs with exposure to Genomic Health, Inc. : September 26, 2017ETFs with exposure to Genomic Health, Inc. : September 26, 2017
finance.yahoo.com - September 26 at 6:50 PM
Genomic Health, Inc. (GHDX) Given Consensus Rating of "Hold" by AnalystsGenomic Health, Inc. (GHDX) Given Consensus Rating of "Hold" by Analysts
www.americanbankingnews.com - September 20 at 4:44 AM
Genomic Health, Inc. (GHDX) Insider Kimberly J. Popovits Sells 5,000 SharesGenomic Health, Inc. (GHDX) Insider Kimberly J. Popovits Sells 5,000 Shares
www.americanbankingnews.com - September 18 at 4:18 PM
Insider Selling: Genomic Health, Inc. (GHDX) COO Sells 5,000 Shares of StockInsider Selling: Genomic Health, Inc. (GHDX) COO Sells 5,000 Shares of Stock
www.americanbankingnews.com - September 14 at 11:36 PM
ETFs with exposure to Genomic Health, Inc. : September 14, 2017ETFs with exposure to Genomic Health, Inc. : September 14, 2017
finance.yahoo.com - September 14 at 7:39 PM
Genomic Health, Inc. (GHDX) Earns "Hold" Rating from Jefferies Group LLCGenomic Health, Inc. (GHDX) Earns "Hold" Rating from Jefferies Group LLC
www.americanbankingnews.com - September 14 at 7:16 PM
Genomic Health, Inc. :GHDX-US: Earnings Analysis: Q2, 2017 By the Numbers : September 13, 2017Genomic Health, Inc. :GHDX-US: Earnings Analysis: Q2, 2017 By the Numbers : September 13, 2017
finance.yahoo.com - September 14 at 2:52 AM
Genomic Health teams up with Biocartis to develop IVD version of Oncotype DX breast cancer testGenomic Health teams up with Biocartis to develop IVD version of Oncotype DX breast cancer test
seekingalpha.com - September 13 at 7:52 AM
Genomic Health and Biocartis Announce Agreement to Develop an Idylla™ IVD Oncotype DX® Breast Cancer Test to Broaden Global Patient AccessGenomic Health and Biocartis Announce Agreement to Develop an Idylla™ IVD Oncotype DX® Breast Cancer Test to Broaden Global Patient Access
finance.yahoo.com - September 13 at 5:54 AM
Biocartis Group NV: Genomic Health and Biocartis Announce Agreement to Develop an Idylla(TM) IVD Oncotype DX® Breast Cancer Test to Broaden Global Patient AccessBiocartis Group NV: Genomic Health and Biocartis Announce Agreement to Develop an Idylla(TM) IVD Oncotype DX® Breast Cancer Test to Broaden Global Patient Access
feeds.benzinga.com - September 13 at 1:27 AM
GHDX Crosses Above Average Analyst TargetGHDX Crosses Above Average Analyst Target
www.thestreet.com - September 12 at 7:50 PM
Genomic Health Presents Data Demonstrating Importance of Oncotype DX Breast Recurrence Score® Test in Predicting Outcomes Across Patient Populations at ESMO 2017Genomic Health Presents Data Demonstrating Importance of Oncotype DX Breast Recurrence Score® Test in Predicting Outcomes Across Patient Populations at ESMO 2017
finance.yahoo.com - September 11 at 7:32 PM
Genomic Health, Inc. breached its 50 day moving average in a Bullish Manner : GHDX-US : September 5, 2017Genomic Health, Inc. breached its 50 day moving average in a Bullish Manner : GHDX-US : September 5, 2017
finance.yahoo.com - September 6 at 1:12 AM
Genomic Health, Inc. (GHDX) Given "Hold" Rating at Cowen and CompanyGenomic Health, Inc. (GHDX) Given "Hold" Rating at Cowen and Company
www.americanbankingnews.com - September 4 at 9:26 PM
Genomic Health Continues to Pioneer Genomic-based Cancer Diagnostics with Multiple Presentations at ESMO 2017 CongressGenomic Health Continues to Pioneer Genomic-based Cancer Diagnostics with Multiple Presentations at ESMO 2017 Congress
finance.yahoo.com - August 31 at 6:57 PM
GHDX Crosses Above Key Moving Average LevelGHDX Crosses Above Key Moving Average Level
www.nasdaq.com - August 30 at 5:37 AM
Genomic Health, Inc. (GHDX) Receives Consensus Rating of "Hold" from BrokeragesGenomic Health, Inc. (GHDX) Receives Consensus Rating of "Hold" from Brokerages
www.americanbankingnews.com - August 26 at 4:34 AM
Genomic Health (GHDX) Says Medicare Establishes Final Local Coverage Determination (LCD) for Use of Oncotype DX GPS TestGenomic Health (GHDX) Says Medicare Establishes Final Local Coverage Determination (LCD) for Use of Oncotype DX GPS Test
www.streetinsider.com - August 25 at 6:02 AM
Medicare Establishes Final Local Coverage Determination (LCD) for Use of the Oncotype DX® Genomic Prostate Score™ Test in Patients with Favorable Intermediate-risk Prostate Cancer Effective October 9, 2017Medicare Establishes Final Local Coverage Determination (LCD) for Use of the Oncotype DX® Genomic Prostate Score™ Test in Patients with Favorable Intermediate-risk Prostate Cancer Effective October 9, 2017
finance.yahoo.com - August 25 at 6:02 AM

Social Media

Financials

Chart

Genomic Health (NASDAQ GHDX) Chart for Friday, November, 17, 2017
Loading chart…

This page was last updated on 11/17/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.